NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/ mTOr phosphorylation

Background: Patients harboring activating mutations in epidermal growth factor receptors (EGFR) are particularly sensitive to EGFR tyrosine kinase inhibitors (TKIs). However, most patients develop an acquired resistance after a period of about 10 months. This study focuses on the therapeutic effect of NVP-BEZ235, a dual inhibitor of phosphatidylinositol-3-kinase/ mammalian target of rapamycin (PI3K/mTOR), in gefitinib-resistant non-small cell lung cancer. Methods: H1975 cell line was validated as a gefitinib-resistant cell model by the nucleotide-sequence analysis. We used the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to detect the growth of H1975 cell line in vitro. H1975 cells’ migration was detected by the migration assay. Xenograft models were used to investigate the growth of gefitinib-resistant non-small cell lung cancer in vivo. Western blot and immunohistochemical analysis were used to investigate the level of PI3K/protein kinase B(AKT)/mTOR signaling pathway proteins. Results: We show that NVP-BEZ235 effectively inhibited the growth of H1975 cells in vivo as well as in vitro. Similarly, H1975 cell migration was reduced by NVP-BEZ235. Further experiments revealed that NVP-BEZ235 attenuated the phosphorylation of PI3K/AKT/mTOR signaling pathway proteins. Conclusion: Taken together, we suggest that NVP-BEZ235 inhibits gefitinib-resistant tumor growth by downregulating PI3K/AKT/mTOR phosphorylation.

[1]  Gang Wu,et al.  NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation , 2015, OncoTargets and therapy.

[2]  Valsamo Anagnostou,et al.  Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells , 2012, PloS one.

[3]  Erin M. Coffee,et al.  The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer , 2011, PloS one.

[4]  W. Berger,et al.  The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells , 2011, Breast Cancer Research and Treatment.

[5]  F. Khuri,et al.  The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo , 2011, PloS one.

[6]  Paul Workman,et al.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic. , 2010, Cancer research.

[7]  Kwok-Kin Wong,et al.  Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition , 2009, Proceedings of the National Academy of Sciences.

[8]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[9]  W. Yung,et al.  NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas , 2009, Molecular Cancer Therapeutics.

[10]  P. Baumann,et al.  The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. , 2009, Experimental cell research.

[11]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[12]  C. Schnell,et al.  Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.

[13]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[14]  J. Engelman,et al.  Acquired resistance to tyrosine kinase inhibitors during cancer therapy. , 2008, Current opinion in genetics & development.

[15]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[16]  D. Tenen,et al.  Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. , 2007, Lung cancer.

[17]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[18]  J. Duyster,et al.  The anticancer drug imatinib induces cellular autophagy , 2007, Leukemia.

[19]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[20]  Gary L Gallia,et al.  PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme , 2006, Molecular Cancer Research.

[21]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[22]  P. Workman,et al.  Drugging the PI3 kinome , 2006, Nature Biotechnology.

[23]  A. Maity,et al.  EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. , 2006, Cancer research.

[24]  P. Vogt,et al.  Phosphoinositide 3-kinase: from viral oncoprotein to drug target. , 2006, Virology.

[25]  J. Miyazaki,et al.  The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. , 2005, Genes & development.

[26]  M. Meyerson,et al.  An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. , 2005, Cancer research.

[27]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[28]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[29]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[30]  Y. Kondo,et al.  Pivotal Role of the Cell Death Factor BNIP3 in Ceramide-Induced Autophagic Cell Death in Malignant Glioma Cells , 2004, Cancer Research.

[31]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[32]  M. Sedlák,et al.  Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. , 2002, Biochemical and biophysical research communications.

[33]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[34]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[35]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[36]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[38]  久保 孝文.  MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors , 2010 .

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.